CR20140228A - Dispersión sólida - Google Patents

Dispersión sólida

Info

Publication number
CR20140228A
CR20140228A CR20140228A CR20140228A CR20140228A CR 20140228 A CR20140228 A CR 20140228A CR 20140228 A CR20140228 A CR 20140228A CR 20140228 A CR20140228 A CR 20140228A CR 20140228 A CR20140228 A CR 20140228A
Authority
CR
Costa Rica
Prior art keywords
solid dispersion
dihydrooxazol
triazolo
quinazoline
yloxy
Prior art date
Application number
CR20140228A
Other languages
English (en)
Inventor
David Shank Fry
Christopher M Lindemann
Michael Preigh
Corey Jay Bloom
Christopher Donovan Craig
Devon Brevard Dubose
Jeff Gautschi
Dan Smithey
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20140228A publication Critical patent/CR20140228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Insulating Materials (AREA)
  • Optical Communication System (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En el presente documento se describe una dispersión sólida de N4-(4-([1,2,4] triazolo [1,5-a]piridina-7-iloxi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooxazol-2-il) quinazolina-4,6-diamina y los procesos para preparar la dispersión sólida. Además, se des
CR20140228A 2011-10-14 2014-05-14 Dispersión sólida CR20140228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547620P 2011-10-14 2011-10-14
US201261606207P 2012-03-02 2012-03-02

Publications (1)

Publication Number Publication Date
CR20140228A true CR20140228A (es) 2014-08-21

Family

ID=47471981

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140228A CR20140228A (es) 2011-10-14 2014-05-14 Dispersión sólida

Country Status (33)

Country Link
US (5) US9457093B2 (es)
EP (1) EP2765990B1 (es)
JP (2) JP5944514B2 (es)
KR (1) KR102000312B1 (es)
CN (3) CN114886853A (es)
AU (3) AU2012322039C1 (es)
BR (2) BR122020010643B1 (es)
CA (2) CA3114454C (es)
CL (1) CL2014000930A1 (es)
CO (1) CO6960547A2 (es)
CR (1) CR20140228A (es)
CY (1) CY1119837T1 (es)
DK (1) DK2765990T3 (es)
ES (1) ES2650608T3 (es)
HR (1) HRP20171578T1 (es)
HU (1) HUE035247T2 (es)
IL (1) IL232103B (es)
LT (1) LT2765990T (es)
ME (1) ME02913B (es)
MX (1) MX353970B (es)
MY (1) MY169072A (es)
NO (1) NO2021029I1 (es)
PH (1) PH12014500799B1 (es)
PL (1) PL2765990T3 (es)
PT (1) PT2765990T (es)
RS (1) RS56608B1 (es)
RU (1) RU2648448C2 (es)
SG (1) SG11201401459YA (es)
SI (1) SI2765990T1 (es)
SM (1) SMT201700499T1 (es)
TW (3) TWI788733B (es)
WO (1) WO2013056108A2 (es)
ZA (1) ZA201606123B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
DK2765990T3 (da) * 2011-10-14 2017-11-13 Array Biopharma Inc Faststofdispersion
KR102317166B1 (ko) * 2012-03-23 2021-10-26 어레이 바이오파마 인크. 뇌암의 치료
CA3128535C (en) * 2013-07-19 2024-10-15 Siga Technologies, Inc. PREPARATION OF AMORPHIC TECOVIRIMAT
EP3082803A4 (en) * 2013-12-20 2017-05-31 Phosphorex Inc. Indirubin solid dispersion composition
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2017148391A1 (zh) 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
IL301979B2 (en) * 2017-03-30 2024-05-01 Merck Patent Gmbh Spray dried solid dispersions comprising (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
JP7244536B2 (ja) * 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
HUE072832T2 (hu) * 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
MX2022004699A (es) 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
EP4058024A1 (en) 2019-11-15 2022-09-21 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) * 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US20230173067A1 (en) 2020-05-29 2023-06-08 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
KR20230047359A (ko) 2020-07-29 2023-04-07 시아겐 인크. 트라스투주맙, 탁산 및 vegfr-2 길항제와 병용하여 투카티닙을 이용하는 her2 양성 암의 치료 방법
CN115340541B (zh) * 2022-07-01 2024-01-30 上海艾洋化学科技有限公司 一种妥卡替尼中间体的制备方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
MX2025007174A (es) * 2022-12-22 2025-07-01 Boehringer Ingelheim Int Dispersion solida de un inhibidor de her2
EP4676543A1 (en) 2023-03-10 2026-01-14 Seagen Inc. Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
CN118084901A (zh) * 2023-12-15 2024-05-28 江苏希迪制药有限公司 妥卡替尼的合成方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
CN1487935A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
KR20040025881A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
PA8629301A1 (es) * 2004-04-08 2006-10-13 Wyeth Corp Formulaciones de acetato de bezedoxifeno
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
EP2140883B1 (en) * 2007-04-20 2012-10-31 Daido Chemical Corporation Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
WO2008138755A2 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
CA2723398C (en) * 2008-05-05 2017-07-04 Abbott Gmbh & Co. Kg Method for evaluating the solubility of a crystalline substance in a polymer
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2253306A1 (en) * 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
DK2765990T3 (da) * 2011-10-14 2017-11-13 Array Biopharma Inc Faststofdispersion
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
KR102317166B1 (ko) 2012-03-23 2021-10-26 어레이 바이오파마 인크. 뇌암의 치료

Also Published As

Publication number Publication date
TWI722189B (zh) 2021-03-21
AU2019200243C1 (en) 2021-04-29
AU2017210499C1 (en) 2021-04-29
CN103998023B (zh) 2018-06-15
CA2852058C (en) 2021-06-01
PT2765990T (pt) 2017-11-14
RU2014119283A (ru) 2015-11-20
AU2012322039C1 (en) 2021-04-29
MY169072A (en) 2019-02-12
WO2013056108A2 (en) 2013-04-18
AU2012322039B2 (en) 2017-08-17
AU2012322039A1 (en) 2014-06-05
RU2648448C2 (ru) 2018-03-26
KR20140075798A (ko) 2014-06-19
SG11201401459YA (en) 2014-07-30
IL232103A0 (en) 2014-05-28
SI2765990T1 (sl) 2017-11-30
US20190275043A1 (en) 2019-09-12
ZA201606123B (en) 2021-05-26
CN103998023A (zh) 2014-08-20
HRP20171578T1 (hr) 2017-12-01
AU2017210499A1 (en) 2017-08-17
NZ624942A (en) 2016-06-24
CN114886853A (zh) 2022-08-12
US9457093B2 (en) 2016-10-04
AU2017210499B2 (en) 2019-01-24
CN108498465A (zh) 2018-09-07
CY1119837T1 (el) 2018-06-27
US20140296267A1 (en) 2014-10-02
CL2014000930A1 (es) 2014-07-18
ME02913B (me) 2018-04-20
PL2765990T3 (pl) 2018-01-31
JP5944514B2 (ja) 2016-07-05
TW202131902A (zh) 2021-09-01
NO2021029I1 (no) 2021-07-09
US20170136022A1 (en) 2017-05-18
CA2852058A1 (en) 2013-04-18
PH12014500799A1 (en) 2014-05-12
TW201330876A (zh) 2013-08-01
US20210220361A1 (en) 2021-07-22
TW201728323A (zh) 2017-08-16
TWI594769B (zh) 2017-08-11
TWI788733B (zh) 2023-01-01
BR112014009092B1 (pt) 2022-01-18
EP2765990A2 (en) 2014-08-20
JP2014528484A (ja) 2014-10-27
WO2013056108A3 (en) 2013-06-27
ES2650608T3 (es) 2018-01-19
JP2016027062A (ja) 2016-02-18
CA3114454A1 (en) 2013-04-18
PH12014500799B1 (en) 2019-04-26
CA3114454C (en) 2022-11-29
DK2765990T3 (da) 2017-11-13
CN108498465B (zh) 2022-05-17
CO6960547A2 (es) 2014-05-30
SMT201700499T1 (it) 2017-11-15
RS56608B1 (sr) 2018-02-28
IL232103B (en) 2018-11-29
LT2765990T (lt) 2018-01-25
HUE035247T2 (hu) 2018-05-02
EP2765990B1 (en) 2017-09-06
MX353970B (es) 2018-02-07
US20230097309A1 (en) 2023-03-30
MX2014004551A (es) 2015-02-12
AU2019200243B2 (en) 2020-06-11
BR112014009092A2 (pt) 2017-04-18
KR102000312B1 (ko) 2019-07-15
BR122020010643B1 (pt) 2022-05-17
AU2019200243A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CY1119837T1 (el) Στερεα διασπορα
CR20140219A (es) POLIMORFOS DE ARRY-380, UN INHIBIDOR SELECTIVO DE ErbB2 Y COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2016001895A1 (es) Compuestos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CL2013003287A1 (es) Compuestos derivados de 5-trifluorometil-4,5-dihidro-isoxazol; compuestos intermediarios; procedimiento de preparacion; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una infestacion de parasitos en animales.
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
UY33078A (es) Derivados de imidazoquinolina
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2014001337A1 (es) Formulacion farmaceutica oral solida que comprende una dispersion solida que comprende a su vez un compuesto especifico derivado de 4-(1-isopropil-1h-pirazol-4-il)-pirimidina y su uso en el tratamiento de una enfermedad proliferativa.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX345351B (es) Compuesto macrociclico y metodos para su produccion.
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
CL2014002497A1 (es) Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
CL2013002908A1 (es) Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia .
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
BR112014009297A2 (pt) processos para a preparação de 6-cloro-2,3,4,9-tetrahidro-1 h-carbazol-1-carboxamida e dos seus precursores
CR20150148A (es) Azaindolinas
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo